[1] Mizrahi JD, Surana R, Valle JW, et al. Pancreatic Cancer[J].Lancet, 2020, 395:2008-2020. [2] Kleeff J, Korc M, Apte M, et al. Pancreatic cancer[J].Nat Rev Dis Primers, 2016, 2:1-22. [3] Manoj A, Ivar G. Pancreatic cancer chemoresistance to gemcitabine[J].Cancers, 2017, 9:157-180. [4] CC Felder, Ma AL, Liotta LA,et al. The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release[J].J Pharmacol Exp Ther,1991, 257:967-971. [5] Stephenson ZA, Harvey RF, Pryde KR, et al. Identification of a novel toxicophore in anti-cancer chemothera-peutics that targets mitochondrial respiratory complex Ⅰ[J].eLife,2020, 9: e55845. doi: 10.7554/eLife.55845. [6] Qin C, Yang G, Yang J,et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies[J].Mol Cancer, 2020,19:50-69. [7] Grover GJ, Kelly J, Moore G, et al.Comparative pharmacokinetic profile of carboxyamidotriazoleand carboxyamidotriazole-orotate[J].Cancer Ther,2007, 5:437-442. [8] Sancho P, Burgos-Ramos E,Tavera A,et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancerstem cells[J].Cell Metab,2015,22:590-605. [9] Rui J,Lei G,Li J,et al. Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts syner-gistic anti-cancer effect with glycolysis inhibition[J]. Cancer Lett, 2016, 370:232-241. [10] Ju R,Fei K,Li S,et al. Metabolic mechanisms and a rational combinational application of carboxyamidotriazole in fighting pancreatic cancer progression after chemotherapy[J].Pharmacol Exp Ther,2018,367:20-27. [11] Pastò A, Pagotto A,Pilotto G, et al. Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells[J].Oncotarget, 2017, 8:6433-6445. [12] Green DR,Galluzzi L,Kroemer G.Mitochondria andthe autophagy-inflammation-cell death axis in organismal aging[J].Science, 2011, 333:1109-1112. |